Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Phase 3 DUO-E/GOG-3041/ENGOT-EN10 Trial - Durvalumab + Carboplatin/Paclitaxel Followed by Maintenance Durvalumab±Olaparib for Newly Diagnosed Advanced/Recurrent Endometrial Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Shannon Westin
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Shannon Westin
Comments 0
Login to view comments.
Click here to Login
